Targeting plasmid-encoded proteins that contain immunoglobulin-like domains to combat antimicrobial resistance.

Alejandro Prieto[1*], Lluïsa Miró[2,3*], Yago Margolles[4], Manuel Bernabeu[1], David Salguero[1], Susana Merino[1], Joan Tomás[1], Juan Alberto Corbera[5], Anna Pérez-Bosque[2,3], Mário Hüttener[1], Luis Ángel Fernández[4] and Antonio Juárez[1,6**]

1. Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain.

2. Department of Biochemistry and Physiology, Universitat de Barcelona, Barcelona, Spain.

3. Institut de Nutrició i Seguretat Alimentària, Universitat de Barcelona, Barcelona, Spain.

4. Department of Microbial Biotechnology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid, Spain.

5. Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Facultad de Veterinaria, Universidad de Las Palmas de Gran Canaria (ULPGC), Campus Universitario de Arucas, Las Palmas, Spain.

6. Institute for Bioengineering of Catalonia, The Barcelona Institute of Science and Technology, Barcelona, Spain.

*Both authors contributed equally to this work.

**Corresponding author: Prof. Antonio Juárez, ajuarez@ub.edu

Running Title: Plasmid-encoded Big proteins targeted to combat antimicrobial resistance

Keywords: Antimicrobial resistance; IncHI plasmids; R27; Big proteins; RSP protein; vaccination; nanobodies; plasmid conjugation.

Abstract

Antimicrobial resistance (AMR) poses a significant threat to human health. Although vaccines have been developed to combat AMR, it has proven challenging to associate specific vaccine antigens with AMR. Bacterial plasmids play a crucial role in the transmission of AMR. Our recent research has identified a group of bacterial plasmids (specifically, IncHI plasmids) that encode large molecular mass proteins containing bacterial immunoglobulin-like domains. These proteins are found on the external surface of the bacterial cells, such as in the flagella or conjugative pili. In this study, we show that these proteins are antigenic and can protect mice from infection caused by an AMR *Salmonella* strain harboring one of these plasmids. Furthermore, we successfully generated nanobodies targeting these proteins, that were shown to interfere with the conjugative transfer of IncHI plasmids. Considering that these proteins are also encoded in other groups of plasmids, such as IncA/C and IncP2, targeting them could be a valuable strategy in combating AMR infections caused by bacteria harboring different groups of AMR plasmids. Since the selected antigens are directly linked to AMR itself, the protective effect extends beyond specific microorganisms to include all those carrying the corresponding resistance plasmids.

Introduction

Despite the availability of antibiotics, bacterial infectious diseases are the second leading cause of death worldwide (Morens et al., 2004; Murray et al., 2022). The gradual increase in the resistance rates of several important bacterial pathogens represents a serious threat to public health (Meyer et al., 2010; Rossolini et al., 2007; Spellberg et al., 2008). In 2019, up to 4,95 million deaths could be associated to antimicrobial resistance (AMR) (Murray et al., 2022).

Plasmids can confer resistance to the major classes of antimicrobials (Carattoli, 2009). Their transmission by horizontal gene transfer (HGT) is largely underlying the dissemination of AMR genes, especially in Gram-negative bacteria (Carattoli, 2013; Thomas and Nielsen, 2005; Wang et al., 2015), but also in Gram-positive bacteria (Vrancianu et al., 2020). Among the various methods utilized for classifying plasmids, grouping them into incompatibility groups (Inc) is a well-established and extensively employed approach (Novick and Richmond, 1965).

The incompatibility group HI includes plasmids that are widespread in the *Enterobacteriaceae*. These plasmids frequently include genetic elements that encode multiple AMR determinants (Phan and Wain, 2008). IncHI-encoded AMR can be present in enterobacteria such as *Salmonella* (Phan and Wain, 2008), *Escherichia coli* (Forde et al., 2018), *Klebsiella pneumoniae* (Villa et al., 2012), and *Citrobacter freundii* (Dolejska et al., 2013). Plasmids of the IncHI2 subgroup predominate in antibiotic-resistant *Salmonella* isolates. In *S. enterica* serotype Typhi, more than 40% of isolates harbor an IncHI plasmid (Holt et al., 2011). Recent reports have shown a novel role of IncHI plasmids in AMR spread. Colistin is a last resort antibiotic for the treatment of severe infections (Lim et al., 2010). Plasmid-mediated resistance, conferred by the mobilized colistin resistance gene (*mcr-1*), has emerged recently. Approximately 20% of global isolates carrying the *mcr-1* gene are associated with an IncHI2 plasmid, and this percentage escalates to 41% when considering exclusively European isolates (Matamoros et al., 2017). Of special concern is the presence of the *mcr-1* resistance determinant in enterobacterial isolates carrying

74 carbapenem resistance genes, such as *blaNDM* and *blaKPC*. The combination of these AMR
75 determinants can seriously compromise the treatment of infections caused by virulent strains
76 harboring these plasmids (Wang et al., 2017; Zheng et al., 2016). An example of this is the recent
77 report of an AMR clone of the highly virulent *E. coli* ST95 lineage (Forde et al., 2018). *E. coli* ST95
78 clones cause neonatal meningitis and sepsis. They are usually sensitive to several antibiotics.
79 This AMR clone harbors an IncHI2 plasmid that carries, among other factors, genes encoding
80 determinants of resistance to colistin and multiple other antibiotics (including the extended-
81 spectrum beta-lactamase $bla_{\text{CTX-M-1}}$ gene cluster). The spread of such an AMR ST95 clone could
82 pose a threat to human health worldwide (Forde et al., 2018).

83 The R27 plasmid is the best studied IncHI1 plasmid. It harbors the Tn10 transposon, which
84 confers resistance to tetracycline. The R27 replicative and conjugative machineries have been
85 studied in detail (Lawley et al., 2003, 2002) and its complete nucleotide sequence is known
86 (Sherburne et al., 2000). A newly reported feature of IncHI plasmids is that they code for large
87 molecular mass proteins that contain bacterial Ig-like (Big) domains (Hüttener et al., 2022, 2019).
88 Bacterial proteins containing Big domains play different roles in the cell. Some fimbrial subunits,
89 adhesins, membrane transporters and enzymes contain Big domains (as reviewed in (Bodelón
90 et al., 2013)). The IncHI1 plasmid R27 encodes the *rsp* and *rsp*2 genes which code respectively
91 for the 155.4 kDa RSP and 86.75 kDa RSP2 proteins. These proteins interact and target both the
92 flagella and the conjugative pili to favor conjugation (Hüttener et al., 2022). Big proteins are also
93 encoded at least by two other groups of plasmids (IncA/C and IncP2) (Hüttener et al., 2022). Due
94 to their extracellular location, these plasmid-encoded Big proteins could be considered as
95 valuable antigens to combat antimicrobial resistance.

96 Functional heavy-chain-only antibodies (HCAbs) were discovered nearly 30 years ago in the
97 serum of camelids (Hamers-Casterman et al., 1993). HCAbs lack both the light chains and the
98 first constant CH1 domain within the heavy chain. The variable domain of HCAbs, also termed

99 VHH for VH of HCAb, represents the smallest antigen-binding unit that occur in nature
100 (Muyldermans, 2013). The VHH domains can be expressed in recombinant form as highly stable
101 single-domain Ab fragments of ~14 kDa, also termed Nanobodies (Nbs), which exhibit high
102 affinity and specificity to its cognate antigens and unique recognition of cryptic epitopes not
103 recognized by conventional Abs (Muyldermans, 2013). Nbs can be easily produced in bacteria
104 and other microbial cultures, and used in multiple diagnostic and therapeutic applications,
105 including bacterial infections (Muyldermans, 2021).

106 In this study, our objective was to investigate the potential of the recently discovered Big
107 proteins encoded by IncHI plasmids as targets for combating antibiotic resistance. Our research
108 focused on two key aspects. First, we examined the efficacy of the RSP protein as a vaccine
109 antigen in providing protection against infections caused by resistant bacteria carrying an IncHI
110 plasmid. The results obtained confirmed the efficacy of the RSP protein as a vaccine antigen.
111 Furthermore, we also generated RSP-specific Nbs and showed that they can interfere with the
112 conjugative transfer of the R27 plasmid. Hence, the use of antigens that are directly linked to
113 AMR determinants can be effective in combating infections caused by AMR bacteria.

114 Results

115 Ampicillin protects mice from infection with the *S.* Typhimurium SL1344 (WT) strain, but not
116 from infection with the *S.* Typhimurium SL1344 (pHCM1) strain.

117 To validate the RSP protein as a vaccine antigen against an antibiotic-resistant *Salmonella* strain,
118 we employed a mouse infection model. We first established that both *Salmonella* strains (WT
119 and pHCM1) were capable of infecting mice, and that only the plasmid-bearing strain was
120 antibiotic resistant. For antibiotic treatment, we specifically selected ampicillin (Amp) due to its
121 established efficacy in reducing the symptoms of *Salmonella* infection in mice (Butler et al.,
122 1981; Rossi et al., 2017).

123 Infection with the *Salmonella* strain SL1344 (WT) reduced the survival rate of the mice by about
124 40% (Fig. 1A), while the addition of Amp increased the survival rate of these animals. On the
125 other hand, Amp treatment did not change the survival of mice infected with strain SL1344
126 (pHCM1).

127 In antibiotic-naive mice infected with either SL1344 (WT) or SL1344 (pHCM1) strains, gradual
128 weight loss and clinical signs of disease were observed (Figs. 1B and 1C). However, Amp
129 treatment only ameliorated these symptoms in mice infected with the SL1344 (WT) strain,
130 showing no effect on those infected with the SL1344 (pHCM1) strain. Additionally, infection with
131 both *Salmonella* strains led to an upregulation of proinflammatory cytokines in the spleen (Fig.
132 1D, 1E, 1F). Amp treatment in mice infected with the SL1344 (WT) strain prevented this increase
133 in cytokine expression.

134 **Immunization of mice with the RSP protein.**

135 We then purified the RSP protein and employed it as a vaccine antigen to evaluate its efficacy in
136 protecting mice against infection caused by the *S*. Typhimurium SL1344 strain carrying the
137 pHCM1 plasmid. To prevent the recurrence of infection by SL1344 clones that spontaneously
138 cured the pHCM1 plasmid in the absence of Amp, we maintained the antibiotic treatment in the
139 immunized animals.

140 The immunization process did not have a significant impact on the body weight progression of
141 the mice (Fig. 2A). Although the overall concentration of total serum IgG remained unchanged
142 following immunization (Fig. 2B), there was a substantial increase in the levels of specific IgG
143 antibodies against the RSP protein (Fig. 2C). In terms of intestinal IgA, immunization resulted in
144 an elevated concentration of total IgA in both the jejunum content and feces (Fig. 2D and 2H,
145 respectively), while not affecting its presence in the colon (Fig. 2F). Moreover, immunization led
146 to enhanced production of specific IgA antibodies against the RSP protein in all three tissue types
147 (intestinal contents Fig. 2E; colon contents Fig. 2G; and feces Fig. 2I).

148 **Effects of immunization of mice on the infection caused by the *S.* Typhimurium SL1344**
149 **(pHCM1) strain.**

150 Survival, body weight evolution and clinical signs

151 Infection with the SL1344 (pHCM1) strain resulted in a decrease in the survival rate of mice and
152 an approximate 20% reduction in their body weight after 6 days of infection. Additionally, it led
153 to an increase in the manifestation of clinical signs associated with infection (Fig. 3). However,
154 immunization significantly improved the survival rate of mice and reduced the incidence of
155 clinical signs in infected animals.

156 Intestinal effects of immunization with the RSP protein and challenge with the SL1344 (pHCM1)
157 strain

158 Immunization with the RSP protein increased the secretion of total IgA into the lumen of the
159 jejunum and colon (Figs. 4A and B), while reducing its concentration in feces (Fig. 4C).
160 Furthermore, immunization with the RSP protein led to an elevated presence of specific IgA
161 antibodies against the RSP protein in all three samples (Fig. 4D-F), with even higher levels
162 observed in infected animals in the case of fecal content. Regarding the expression of
163 proinflammatory cytokines, infection with the SL1344 (pHCM1) strain resulted in increased
164 expression of all three cytokines analyzed (Fig. 4G-I) both in immunized and non-immunized
165 animals. In the case of *Tnf-α*, immunization also increased its expression.

166 Systemic effects of immunization with the RSP protein and challenge with the SL1344 (pHCM1)
167 strain

168 The immunization protocol also resulted in an increase in the concentration of total IgG at the
169 systemic level (Fig. 5A), while infection with the SL1344 (pHCM1) strain reduced it. Additionally,
170 immunization also led to an elevated concentration of specific anti-RSP IgG in the serum (Fig.
171 5B), which remained unaffected after infection with the SL1344 (pHCM1) strain. Following

172 bacterial challenge, the spleen weight increased nearly threefold in non-immunized mice (Fig.
173 5C). In contrast, immunized mice exhibited a significantly lower increase in spleen weight.
174 Furthermore, animals infected with the SL1344 (pHCM1) strain displayed *Salmonella*
175 colonization in the spleen (Fig. 5D), which was significantly reduced in immunized animals.
176 Regarding the expression of proinflammatory cytokines in the spleen, *Salmonella* infection
177 upregulated the expression of all cytokines evaluated (Fig. 5E-G). Immunization partially
178 mitigated this effect on Il-1β and Tnf-α expression.

179 **Selection of nanobodies with neutralizing activity against the RSP protein**.

180 Given the protective effect against *Salmonella* infection observed in mice immunized with the
181 RSP protein, we wondered whether we could obtain specific antibodies against RSP that could
182 directly interfere with its biological activity in the conjugative transfer of IncHI plasmids. We
183 chose nanobodies as ideal candidates to block RSP activity given their small size, stability and
184 high affinity to antigens, and their therapeutic potential against infections. Interestingly,
185 nanobodies can also be expressed on the surface of *E. coli* fused to the initial 654 amino acids
186 of the enterohemorrhagic *E. coli* intimin protein, termed Neae (Bodelón et al., 2009), comprising
187 the N-terminal signal peptide, the periplasmic LysM domain, the β-barrel for outer membrane
188 insertion, and the extracellular Big domains D00 and D0 (Fairman et al., 2012). Expression of
189 Neae-Nb fusions represent an efficient bacterial display system for their selection of Nbs binding
190 a target antigen from VHH gene libraries employing *E. coli* cell sorting methods with the labelled
191 antigen (Salema et al., 2013; Salema and Fernández, 2017). In addition, Neae-Nb fusions
192 expressed in *E. coli* promote synthetic cell-to-cell adhesions mediated by the specific recognition
193 of a surface antigen in the target cell (Glass and Riedel-Kruse, 2018; Piñero-Lambea et al., 2015).
194 In order to obtain Nbs that specifically bind the extracellular domain of the RSP protein, we
195 immunized two dromedaries with the last 280 residues of the C-terminal domain of the RSP
196 protein. After immunization, peripheral blood lymphocytes from these animals were isolated

197 and the VHH gene segments were amplified and cloned in the display vector pNeae2 (Robledo
198 et al., 2022; Salema et al., 2013), which encodes the Neae intimin fragment under the control of
199 the IPTG-inducible lacI-Plac promoter region. A library of approximately $1x10^8$ clones was
200 obtained by electroporation of *E. coli* DH10BT1R strain with the products of the ligated pNeae2-
201 VHH. Bacteria in library were grown in liquid culture and induced with IPTG. Induced bacteria
202 binding the C-domain of RSP were selected by incubation with the purified protein labeled with
203 biotin, following iterative steps of magnetic cell sorting (MACS) and fluorescence-assisted cell
204 sorting (FACS) (Materials and Methods). After the final sorting step (Fig. 6A), the selected pool
205 of bacteria was grown on LB-agar plates. 96 colonies were randomly picked from these plates,
206 grown in liquid, and induced with IPTG to evaluate the Nb display levels on the bacterial surface
207 and their binding capability to the biotinylated C-domain of the RSP protein by flow cytometry
208 (Fig. 6B). The VHH sequences from clones with specific binding to purified RSP were determined,
209 which allowed us to identify 7 different Nbs (Supplementary Fig. 1).

210 **Selection of Nb clones displayed on *E. coli* that agglutinate with the *S*. Typhimurium SL1344**
211 **(R27) strain.**

212 For selection of Nbs binding native RSP expressed on *Salmonella* cells, we took advantage of the
213 specific adhesion observed between *E. coli* cells with displayed Nbs and bacteria having the
214 target antigen accessible on their surface, which leads to the agglutination of mixed bacterial
215 cultures (Glass and Riedel-Kruse, 2018; Robledo et al., 2022).

216 We initially evaluated the agglutination capability of the 7 different clones obtained in the
217 enrichment protocol of the immune library, from strain *E. coli* DH10BT1R, each carrying a
218 pNeae2-VHH derivative expressing RSP-specific Nbs, against the *S*. Typhimurium SL1344 (R27)
219 strain. To achieve this, we cultured the *Salmonella* strain in LB medium to an $OD_{600\ nm}$ of 2.
220 Following centrifugation, cells were resuspended in PBS and mixed with an equal volume of a
221 culture of the different *E. coli* DH10BT1R clones displaying the different set of RSP-specific Nbs.
222 Only one of the clones tested (Nb 3) showed ability of agglutinating the *S*. Typhimurium SL1344

223 (R27) strain (Fig. 7A). Next, we inspected this phenomenon using electron microscopy (Fig. 7B)
224 The presence of the R27 plasmid dictated the formation of clumps between the SL1344 strain
225 and *E. coli* DH10BT1R (pNeae2 VHH-RSP #3). In contrast, no clumps or aggregates were observed
226 when the plasmid-free SL1344 or the SL1344 (R27 Δ*rsp*) strains were used.
227 To further characterize this clone, the corresponding VHH gene was cloned in the mammalian
228 expression vector pIgΔCH1 (Casasnovas et al., 2022), which allows the fusion of the selected Nb
229 domain to the Fc region of human IgG1. The corresponding Nb3-Fc protein fusion was purified
230 from culture supernatants of transfected Expi293F cells (Fig. 8A), and its binding capacity to the
231 RSP protein was analyzed by ELISA. The results indicated that this Nb3-Fc presented a high
232 affinity for binding to the RSP protein, showing an apparent equilibrium dissociation constant
233 (K_D) in the picomolar range (~44 pM) (Fig. 8B).

234 **Interference of *E. coli* displaying Nb-RSP #3 strain on the conjugation of the R27 plasmid from**
235 **the *Salmonella* Typhimurium SL1344 strain.**

236 Our objective was to investigate whether the *E. coli* surface expression of the Nb-RSP #3 would
237 be able interfere with the conjugation process of the R27 plasmid from the SL1344 *Salmonella*
238 strain (donor) to the SL1344 *ibpA::lacZ-Km*^{r} derivative (recipient). To prevent that the Nbs
239 produced by the *E. coli* DH10BT1R (pNeae2 VHH-RSP #3) were titrated out by an excess of
240 SL1344 (R27) donor cells, we planned a conjugation experiment with a low number of donor
241 cells (10^3 cfu) mixed with an abundance of recipient cells (SL1344 *ibpA::lacZ-Km*^{r}) (10^6 cfu), along
242 with an excess of cells corresponding to the *E. coli* strain displaying Nb-RSP #3 (10^7 cfu).

243 Considering the known conjugation frequency of the R27 plasmid in *Salmonella* at 25°C, which
244 is approximately 10^{-3}, and the low number of donor cells used in our experiment, we chose
245 specific time intervals of 24, 36 and 48 hours following the mating process to detect
246 transconjugants within the mating mixture. To accomplish this, the mating mixture was mixed
247 with PB medium and incubated at 25°C. To confirm that any effect on the conjugation frequency

248 was solely due to the production of RSP-specific Nbs and not to other non-specific effects of Nb
249 expression, we utilized as controls both a plasmid-free *E. coli* DH10BT1R strain and the same
250 strain displaying an unrelated Nb binding human fibrinogen (Salema et al., 2016). The results
251 obtained (Fig. 9) indicated that the surface display of Nb-RSP #3 by the interfering *E. coli* strain
252 led to a significant and specific reduction in the conjugation frequency of the R27 plasmid in the
253 *S.* Typhimurium SL1344 strain. Interfering *E. coli* strains with no Nb or a control Nb elicited a
254 nonspecific ~10-fold reduction in the number of transconjugants of R27 plasmid in all time
255 points, compared to conjugation levels between *Salmonella* SL1344 strains. In contrast,
256 interfering *E. coli* displaying Nb-RSP #3 reduced the number of transconjugants of R27 up to
257 ~1000-fold at 24h and ~100-fold after 36 and 48h of mating (Fig. 9). These results suggest a
258 strong inhibitory effect in the conjugation of R27 due to the interaction between bacterial
259 display Nb-RSP #3 and RSP protein expressed by donor cells. To rule out that the observed
260 reduction in the conjugation frequency in mixtures containing the *E. coli* strain DH10BT1R
261 (pNeae2 VHH-RSP #3) and the SL1344 (R27) strains could be due to the specific transfer of the
262 R27 plasmid to the interferent *E. coli* DH10BT1R (pNeae2 VHH-RSP #3) strain, we also detected
263 transconjugants of the *E. coli* DH10BT1R (pNeae2 VHH-RSP #3) and *E. coli* DH10BT1R (pNVFib1)
264 interferent strains by plating them on LB medium containing Tc (R27 plasmid marker) and Cm
265 (pNeae2 plasmid marker). In both experiments the conjugation frequency was the same ($1.5x10^{-}$
266 ^{2} transconjugants/donor cells).

267 **Discussion**

268 Vaccination stands as a priority strategy in addressing the challenges posed by AMR (Frost et al.,
269 2022; Micoli et al., 2021). Vaccines of special interest should target the agents responsible for
270 significant health care-associated infections, which include multiple resistant Gram-negative
271 bacteria (Lipsitch and Siber, 2016). Protecting against specific pathogens (i.e., *S. pneumoniae, K.*

272 *pneumoniae*) reduced the incidence of infections caused by them, leading to a decrease in
273 antibiotic usage and hence reducing the proliferation of AMR strains (Buchy et al., 2020).

274 One of the challenges in vaccine development is the identification of broadly protective antigens
275 (Troisi et al., 2020). In the context of AMR, current strategies focus on targeting either the most
276 common antigens among AMR clones of a specific pathogen (Micoli et al., 2021) or specific
277 virulence determinants (Moriel et al., 2010; Nesta et al., 2012). However, an alternative
278 approach is to develop a vaccine that directly targets a resistance determinant, which would be
279 effective not only against a specific microorganism but also against any microorganism
280 expressing the corresponding resistance determinant. Examples of successful targeting include
281 penicillin-binding proteins or beta-lactamases, which have demonstrated protection against
282 infections caused by *Staphylococcus aureus* (Senna et al., 2003), *Neisseria meningitidis*
283 (Zarantonelli et al., 2006), or *Pseudomonas aeruginosa* (Ciofu et al., 2002).

284 The novelty of the approach presented in this work is that, instead of targeting an antigen
285 involved in an antibiotic resistance mechanism, we focus on an antigen associated with the
286 transmission of resistance determinants.

287 Big proteins have been previously shown to be good vaccine candidates (Khanum et al., 2022;
288 Koizumi and Watanabe, 2004). The antigenicity of the RSP protein has been demonstrated by
289 the presence of higher levels of specific immunoglobulin, IgG in serum and IgA in the colon,
290 jejunum, and feces. In terms of the protective effect of immunization with the RSP protein in
291 mice, the results can be interpreted as follows. The secretion of proinflammatory cytokines in
292 the colon was comparable between immunized and non-immunized animals, as well as the
293 reduction in body weight. However, clinical symptoms, *Salmonella* counts in the spleen, and the
294 weight and secretion of proinflammatory cytokines in this organ were significantly reduced in
295 immunized animals. While immunization with the RSP protein did not provide complete
296 protection against intestinal infection with the SL1344 strain, it did result in attenuated disease

297 symptoms and restricted systemic infection. These findings support further research to validate
298 the RSP protein as a valuable antigen for protection against bacterial infections caused by enteric
299 bacteria harboring IncHI plasmids.

300 IncHI plasmids are commonly found in AMR bacteria isolated from clinical samples (Parvez and
301 Khan, 2018; Zhang et al., 2021). They are also frequently identified in *Salmonella* isolates (Phan
302 and Wain, 2008). The emergence of AMR *S. typhi* isolates has been reported in developing
303 countries (Tanmoy et al., 2018). Developing an effective vaccine against this pathogen would be
304 particularly beneficial for children in endemic countries, including regions such as South Asia,
305 Southeast Asia, and sub-Saharan Africa, as well as for travelers (World Health Organization,
306 2019). The RSP protein shows promise as a valuable antigen to be included in such a vaccine,
307 offering potential protection against AMR *Salmonella* infections associated with IncHI plasmids.

308 An alternative approach to provide protection against infections caused by virulent AMR strains
309 carrying IncHI plasmids is to specifically target the RSP protein with antibodies. Monoclonal
310 antibodies against various bacterial pathogens have demonstrated effectiveness, with some
311 currently in advanced stages of clinical trials (Cook and Wright, 2022). Nanobodies, a novel class
312 of antibodies, offer a wide range of clinical applications (Graf et al., 2019; Jovčevska and
313 Muyldermans, 2020a). The use of nanobodies specifically targeting the RSP protein represents
314 a promising approach to combat infections caused by pathogenic bacteria harboring IncHI
315 plasmids. Inhibiting the transfer of antimicrobial resistance plasmids has been identified as a
316 crucial strategy to combat AMR (Buckner et al., 2018; Graf et al., 2019). Our study demonstrates
317 that *E. coli* strains producing RSP-specific nanobodies can bind to *Salmonella* cells carrying the
318 R27 plasmid, resulting in a reduction in the conjugation frequency.

319 Expressing RSP-specific nanobodies in a probiotic bacterium, such as *E. coli* Nissle 1917, can help
320 restrict the transfer of IncHI plasmids in natural environments. Furthermore, RSP-specific
321 antibodies could be utilized to combat infections caused by pathogenic isolates carrying IncHI
322 plasmids. Nanobodies, known for their heat- and acid-stability and solubility, show potential for

323 oral administration to control gastrointestinal infections (Yuki et al., 2023). Thus, either purified
324 RSP-specific nanobodies or probiotic microbial cells expressing these nanobodies could be orally
325 administered to combat infections caused by AMR virulent strains harboring IncHI plasmids.

326 The expression of plasmid-encoded Big proteins is not exclusive to IncHI plasmids; other
327 plasmids such as IncA/C and IncP2 also encode these proteins (Hüttener et al., 2022). IncA/C
328 plasmids were initially identified in the 1970s among multidrug-resistant *Aeromonas hydrophila*
329 and *Vibrio* strains that infected cultured fish (Aoki et al., 1971). Since the 1990s, IncA/C plasmids
330 have gained significant attention due to their ability to mobilize antimicrobial resistance
331 determinants in enterobacteria and other Gram-negative microorganisms (Call et al., 2010;
332 Fernández-Alarcón et al., 2011; Fricke et al., 2009; Welch et al., 2007). These plasmids have an
333 exceptionally wide host range, encompassing Beta-, Gamma-, and Deltaproteobacteria (Suzuki
334 et al., 2010), and they play a crucial role in the global dissemination of antimicrobial resistance
335 (Eda et al., 2020; Rozwandowicz et al., 2018). In a recent study, IncA/C plasmids accounted for
336 50% of all plasmids isolated from clinical *K. pneumoniae* strains harboring the *blaNDM* gene
337 (Qamar et al., 2021). Notably, the monophasic variant of *S*. Typhimurium, *S. enterica* serovar
338 4,[5],12:i:-, which has emerged as a global cause of multidrug-resistant salmonellosis,
339 predominantly harbors IncHI1 and IncA/C resistance plasmids (Ingle et al., 2021).

340 Therefore, targeting these plasmid-encoded Big proteins through immunotherapies can be a
341 valuable strategy to combat infections caused by pathogenic microorganisms carrying various
342 types of resistance plasmids.

343 Methods

344 Bacterial strains and growth conditions.

345 The bacterial strains (see Supplementary Table S1) were routinely grown in Luria-Bertani (LB)
346 medium (10 g/L NaCl, 10 g/L tryptone and 5 g/L yeast extract) with vigorous shaking at 200 rpm

347 (Innova 3100; New Brunswick Scientific). The antibiotics used were chloramphenicol (Cm) (25
348 µg/mL), tetracycline (Tc) (15 µg/mL), carbenicillin (Cb) (100 µg/mL), and kanamycin (Km) (50
349 µg/mL) (Sigma-Aldrich). *E. coli* strains carrying the plasmid with a VHH gene were grown at 30ºC
350 on LB-agar plates (1.5% w/v) or in LB liquid medium with the addition of chloramphenicol (Cm,
351 30 µg/mL) for plasmid selection. To overexpress the nanobodies in the bacterial surface of *E.*
352 *coli* DH10BT1R, firstly bacteria were grown overnight (O/N) under statics conditions in LB
353 medium containing 2% (w/v) of glucose. Then, bacteria were harvested by centrifugation (4000
354 g for 5 minutes) and grown in the same media supplemented with 0.05 mM isopropylthio-β-D-
355 galactoside (IPTG) in constant agitation (160 rpm) for 16 hours.

356 **Plasmids.**

357 The different plasmids used in this work are listed in Supplementary Table S1.

358 **Oligonucleotides.**

359 The oligonucleotides used in this work are listed in Supplementary Table S2.

360 **Genetic manipulations.**

361 All enzymes used to perform standard molecular and genetic procedures were used according
362 to the manufacturer's recommendations. To introduce plasmids into *E. coli, Salmonella* and
363 *Klebsiella*, bacterial cells were grown until an $O.D_{600\ nm}$ of 0.8. Cells were then washed several
364 times with 10% glycerol, and the respective plasmids or DNA were electroporated by using an
365 Eppendorf gene pulser (Electroporator 2510).
366 Deletion of the *flhDC* locus was performed in the strain SL1344 by using the λ Red recombination
367 method, as previously described (Datsenko and Wanner, 2000).

368 **Conjugative transfer of the R27 plasmid**.

369 The R27 plasmid was conjugated as described previously (Hüttener et al., 2019). The mating
370 frequency was calculated as the number of transconjugants per donor cell.

371 **Purification of the native RSP protein for the immunization assay.**

372 The RSP protein was purified from cell-free supernatant fractions obtained from the *Salmonella*
373 cells lacking the flagella (SL1344 R27 *flhDC::Km*). Cells were grown at 25ºC in LB medium for 16
374 hours in constant shaking at 200 rpm, then centrifugated at 7000 rpm for 30 minutes at room
375 temperature. Cell pellets were discarded, and the supernatant was filtered through a 0.22 μm
376 filter (Millipore). Supernatants were then ultra-centrifugated at 40000 rpm for 1 hour at 4ºC and
377 carefully aspired to not disturb the protein pellet and discarded. The remaining pellet was
378 solubilized using commercial Phosphate-buffered saline (PBS – Gibco). Proteins were quantified
379 using the Bradford standard method (Pierce).

380 **Purification of the C-terminal domain of the RSP protein.**

381 For the RSP protein production the carboxyl-terminal region of the RSP protein was amplified
382 (280 AA in total). Amplification of that region was achieved by performing PCR using the R27
383 plasmid as a DNA template and the primers RSP5 BamHI Fw and RSP PstI Rv, together with the
384 Phusion Hot Start II High-fidelity DNA Polymerase (Thermo Fisher Scientific) following the
385 manufacturer's recommendations. The DNA was then purified using the GeneJet PCR
386 Purification Kit (Thermo Fisher Scientific), digested with BamHI and PstI restriction
387 endonucleases according to the manufacturer´s instructions (New England Biolabs), and ligated
388 into the pMAL-p2E vector digested with the same restriction endonucleases using the T4 DNA
389 Ligase (New England Biolabs) according to the manufacturer´s instructions. The resulting
390 plasmid, termed pMAL-RSP#5/7, was Sanger sequenced and transformed into BL21 cells. Cells
391 transformed with pMAL-RSP#5/7 plasmid were grown in LB medium supplemented with
392 carbenicillin at a final concentration of 100 µg/mL at 37°C for 16 hours at constant agitation at
393 200 rpm. Then, cells were diluted 1:100 in LB with 100 µg/mL of carbenicillin and glucose at
394 0.45% of the final concentration. Cells were incubated at 37ºC with 200 rpm until reached the
395 $O.D_{600\ nm}$ of 0.5, then IPTG was added at a final concentration of 0.15 mM. Cells were incubated

396 at 37ºC for 2 hours under constant agitation of 200 rpm for the induction of the recombinant
397 protein. Cells were then centrifuged at 7500 rpm for 30 minutes at 4°C. The cells pellet was
398 subsequently resuspended in column buffer (20 mM HEPES (Na) pH 7.5, 200 mM NaCl, 1 mM
399 EDTA, 1 mM β-mercaptoethanol) plus protease inhibitor (Complete Ultra Tablets, Mini, EDTA-
400 free, EASYpack, Roche). Cells were then disrupted by French press cell lysis and centrifugated at
401 12000 rpm for 1 hour at 4°C. Supernatants were filtered through a 0.22 μM filter (Millipore) and
402 mixed with 250 μl of Amylose resin (New England Biolabs) for 2 hours at 4ºC in an orbital shaker.
403 The resin was then loaded in chromatography columns and washed twice with the column
404 buffer. The recombinant RSP C-terminal protein was then eluted using the elution buffer (20
405 mM HEPES (Na) pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM β-mercaptoethanol and 10 mM
406 maltose). Eluted fractions were collected and then concentrated using Amicon Ultra-15 Ultracel
407 10K (Millipore) according to the manufacturer´s instructions.

408 **Immunization of dromedaries with the C-terminal fragment of the RSP protein and selection**
409 **of clones producing anti-RSP specific nanobodies.**

410 Two different dromedary camels (*Camelus dromedarious*) were immunized with purified RSP
411 protein (~1.2 mg) mixed with veterinary vaccine adjuvant (GERBU). After 6 rounds of
412 inoculations by subcutaneous injections, serial dilutions of pre-immune and immune sera were
413 used in ELISA to confirm the immune response of dromedary after the RSP protein inoculation.
414 B lymphocytes from peripheral blood were isolated, RNA was extracted and VHH genes were
415 amplified by RT-PCR using the VHH Sfi and VHH Not oligonucleotides following the protocol
416 described previously (Salema et al., 2013).

417 The amplified VHH fragments were digested with SfiI and NotI restriction enzymes and ligated
418 into the pNeae2 backbone vector digested with the same restriction enzymes, and finally
419 transformed in *E. coli* DH10BT1R by electroporation. Following this protocol, a library of 8.75×10^7
420 clones was obtained.

421 This library was used for the enrichment of clones that recognized the RSP protein. To this end,
422 purified RSP protein was mixed with Biotin-NHS (Biotinamidocaproate N-hydroxysuccinimide
423 ester, Sigma Aldrich) and three rounds of MACS (with RSP concentrations of 100 nM (the first
424 one) and 50 nM (the other two)) were performed. Thereafter, a FACS selection with a protein
425 concentration of 50 nM were performed). The positive clones for the RSP binding were selected
426 for further analysis.

427 **Cloning and purification of the RSP specific nanobody (VHH-RSP #3).**

428 The gene coding for the RSP-specific selected Nb was PCR amplified with oligonucleotides VHH
429 pIg AgeI and VHH pIg BamHI using the pNeae2 VHH-RSP #3 purified plasmid as a template. This
430 PCR product was subsequently cloned in AgeI-BamHI sites of the mammalian expression vector
431 pIgΔCH1 (Casasnovas et al., 2022) derived from pIgγ1HC (Tiller et al., 2008). This vector allows
432 the expression of the cloned gene located in frame with a IgH signal peptide fused to the human
433 IgG1 hinge and Fc portion. For the nanobody overexpression and purification, the Expi293™
434 Expression System Kit (Thermo Fisher Scientific) was used. The mammalian cells transfected with
435 the purified expression vector (pIgΔCH1 VHH-RSP) were grown 5 days post-transfection. Cells
436 were then centrifuged, the supernatant was collected and filtered, and the proteins were
437 purified with an Ig Select or protein A affinity columns (Cytiva), following manufacturer's
438 instructions.

439 **Enzyme-linked immunosorbent assays to evaluate the specific VHH-RSP #3 binding to the RSP**
440 **protein.**

441 ELISA experiments were performed in 96-well plates (Maxisorp, Nunc), which were previously
442 coated overnight at 4°C with 50 µl/well of the purified RSP protein antigen or BSA at 3 µg/ml in
443 PBS. Antigen-coated plates were washed with PBS and blocked with 200 µl/well of 3% (w/v)
444 skimmed milk in PBS at room temperature for 2 h. Afterwards, different dilutions of the VHH-
445 RSP (prepared in 3% (w/v) skimmed milk in PBS) were added to the wells for 1 h. After the

446 incubation, the wells were washed three times with PBS, and rabbit anti-human Fc IgG-HRP
447 (Jackson ImmunoResearch) was added to the plates (diluted 1:5000 in 3% (w/v) skimmed milk
448 in PBS) to detect the bound Nbs. After 1 h of incubation at room temperature, plates were
449 washed with PBS and developed with H_2O_2 and o-phenylenediamine (OPD; Merck-Sigma). The
450 Optical Density (OD) at 490 nm ($OD_{490\ nm}$) of plate wells was determined (iMark, Bio-Rad), and
451 the values were corrected with the background levels of OD_{490nm} of the wells without antigen
452 added.

453 ***In vivo* immunization and infection of mice.**

454 Male and female C57BL/6 mice were purchased from Envigo (Bresso, Italy) and maintained
455 under stable temperature and humidity conditions with a 12-hour light 12-hour dark cycle and
456 free access to food and water.

457 Set up of the infection protocol with the SL1344 (pHCM1) strain.

458 To induce infection, the *S.* Typhimurium strain SL1344 (pHCM1) was chosen. An assay was
459 designed to assess whether infection with this strain is similar to infection with the plasmid-free
460 strain. Four groups of mice were infected with strains SL1344 and SL1344 (pHCM1), and two of
461 them were treated with 150 mg/kg/day ampicillin (Amp) (Sigma-Aldrich) in drinking water and
462 two of them were untreated. In addition, a group of uninfected control mice was included as a
463 reference group. Thus, the groups were: i) Control: uninfected mice; ii) Sal: SL1344-infected mice
464 not treated with Amp; iii) Sal-pHCM1: SL1344-pHCM1-infected mice not treated with Amp; iv)
465 Sal WT + Amp: SL1344-infected mice treated with Amp; v) Sal pHCM1 + Amp: SL1344-pHCM1-
466 infected mice treated with Amp. Three hours before the challenge with the bacterial suspension,
467 mice received an intraperitoneal injection of cimetidine (50 mg/kg; Sigma-Aldrich) to reduce acid
468 secretion and improve bacterial survival(Ren et al., 2014). To induce infection, 100 µl of the
469 bacterial suspension (10^9 cfu of *Salmonella*) was administered by oral gavage. During the
470 infection period the body weight of animals was monitored daily. Four to six days after infection

471 (depending on survival), the animals were evaluated for clinical signs of disease and fecal
472 samples were obtained. They were subsequently euthanized and samples of spleen, colon
473 mucosa, intestinal lavage and serum were obtained. Samples were obtained and processed as
474 described previously (Miró et al., 2023).

475 The parameters analyzed to score the clinical signs were: Coat care (normal, 0; slightly altered,
476 1; considerably altered, 2; very altered, 3); posture (normal, 0; slightly curved, 1; considerably
477 curved, 2; very curved, 3); movement (normal, 0; slightly slow, 1; considerably slow, 2; very slow,
478 3); defecation (normal, 0; soft stools, 1; watery stools, 2; liquid stools, 3); body weight loss (no
479 weight loss, 0; weight loss less than 5%, 1; weight loss between 5 and 10%, 2; weight loss greater
480 than 10%, 3).

481 Immunization with the RSP protein and infection with the *S.* Typhimurium SL1344 (pHCM1)
482 strain.

483 Regarding the adjustment of the immunization with the RSP protein as antigen, we proceeded
484 as previously described (Miró et al., 2023). Briefly, mice were intranasally administered with 3
485 µg of the RSP protein and 5 µg of cholera toxin (CT; Sigma-Aldrich) as immunological adjuvant.
486 Immunization was performed 3 times every 2 weeks (at 3, 5 and 7 weeks of age). Non-
487 immunized mice received CT alone. Mice were distributed randomly into two groups: Non-Imm
488 (Non-immunized, CT alone); Imm (Immunized mice). During the immunization period the body
489 weight of animals was monitored weekly. Two weeks after last immunization, animals were
490 euthanized and samples of feces, intestinal lavage and serum were obtained. Total and RSP-
491 specific immunoglobulins were determined as explained in the section Immunoglobulin
492 determination.

493 In order to evaluate the protective efficacy of immunization, the previously established infection
494 protocol with the *S.* Typhimurium SL1344 (pHCM1) strain was used. The experiments were
495 performed using a Latin design with two factors: immunization of mice using the RSP protein as

496 immunogen; and subsequently infected with the *S.* Typhimurium SL1344 (pHCM1) strain. The
497 animals were randomly distributed into four groups: i) non-immunized and non-infected mice
498 (Non-Imm); ii) non-immunized and *Salmonella*-infected animals (Sal); iii) immunized and non-
499 infected animals with *Salmonella* (Imm); iv) immunized and infected animals (Imm-Sal). The
500 infection was provoked two weeks after last immunization dose.

501 **Bacterial counts in spleen.**

502 Spleen samples were homogenized with sterile PBS (20 mg/mL) using a PRO200 homogenizer
503 (Pro-Scientific, USA) at 18000 g, and homogenates were used to count the presence of
504 *Salmonella* cells plated in MacConkey media agar plates.

505 **Immunoglobulin concentration.**

506 Total secreted IgA and anti-RSP-specific IgA were determined in intestinal and colon content and
507 in feces by sandwich enzyme-linked immunosorbent assay (ELISA) as previously described (Ren
508 et al., 2014). Briefly, plates were coated with anti-mouse IgA monoclonal antibody (1 µg/mL;
509 Sigma-Aldrich) in PBS to quantify total IgA concentration or RSP (20 µg/mL) in PBS to measure
510 RSP-specific IgA concentration. Mouse IgA (Bethyl) was used as a standard for the determination
511 of total IgA. Goat anti-mouse IgA (Bethyl) conjugated with horseradish peroxidase (HRP) was
512 used as the detection antibody.

513 The concentrations of total IgG and specific IgG against the RSP protein in serum were also
514 determined. Plates were coated with goat anti-mouse IgG (1 µg/mL; Sigma-Aldrich) to quantify
515 the concentration of total IgG or RSP (10 µg/mL) in PBS to measure the concentration of specific
516 IgG against RSP. Mouse IgG (Sigma-Aldrich) was used as a standard for the determination of
517 total IgG. Goat anti-mouse IgG conjugated with HRP (Sigma-Aldrich) was used as detection
518 antibody.

519 In all cases, o-phenylenediamine (OPD, 0.4 mg/mL; Sigma-Aldrich) was used as HRP substrate,
520 and the color intensity was measured at 492 nm in a microplate reader (Sunrise).

521 **Cytokine expression in spleen and colon.**

522 RNA extraction and reverse transcription were carried out as previously described (Rosell-
523 Cardona et al., 2022). RNA quality and quantity were assessed by spectrophotometry (NanoDrop
524 ND-1000; Thermo Fisher Scientific) and its integrity was determined with an Agilent 2100
525 Bioanalyzer (Agilent Technologies Inc.). In all cases, the RNA integrity was ≥ 9 and the A260/280
526 ratio was between 1.96 and 2.02. Total RNA was reverse-transcribed using an iScript™ cDNA
527 Synthesis Kit (Bio-Rad). For real-time PCR determinations, we used SsoAdvanced™ Universal
528 SYBR® Green Supermix (Bio-Rad). The primers used are described previously (Garcia-Just et al.,
529 2020). Real-time PCR was performed on a MiniOpticon Real-Time PCR System (Bio-Rad). Each
530 PCR run included duplicates of reverse transcript cDNA for each sample and negative controls
531 (reverse transcription-free samples, RNA-free sample). Quantification of the target gene
532 transcripts was conducted using hypoxanthine phosphoribosyl transferase 1 (*hprt1*) gene
533 expression as reference and was performed with the $2^{-\Delta\Delta CT}$ method (Schmittgen and Livak,
534 2008). Product fidelity was confirmed by melting curve analysis.

535 **Immunogold electron microscopy.**

536 Immunogold microscopy experiments were performed as previously described (Hüttener et al.,
537 2019).

538 **Statistical analysis.**

539 The results of mice experiments are presented as mean ± SEM, except for survival curves and
540 disease indices. Survival curves have been compared by Log-rank (Mantel-Cox) test and
541 expressed as a percentage of survival. Disease indices are expressed as median values and
542 quartiles and have been compared by the Kruskal-Wallis test. Continuous data were analyzed

543 with Levene's test to assess the homogeneity of variance and with the Shapiro-Wilk test to
544 assess distribution. Homogeneous and normally distributed data were analyzed with Student's
545 t-test (immunization-tuning experiments) or one-way analysis of variance (ANOVA) (infection-
546 tuning) followed by Fisher's least significant difference (LSD) post hoc test and two-way ANOVA
547 (immunization and infection experiments). Student's t-test was also used to determine
548 statistical significance of R27 conjugation frequency in mating experiments. Data were analyzed
549 using GraphPad Prism® software v.9.3.1 (GraphPad Software, Inc.). Differences were considered
550 significant at $P<0.05$.

551 **References**

552 Aoki T, Egusa S, Kimura T, Watanabe T. 1971. Detection of R factors in naturally occurring
553 *Aeromonas salmonicida* strains. *Appl Microbiol* **22**:716–717. doi:10.1128/aem.22.4.716-
554 717.1971

555 Bodelón G, Marín E, Fernández LA. 2009. Role of Periplasmic Chaperones and BamA
556 (YaeT/Omp85) in Folding and Secretion of Intimin from Enteropathogenic *Escherichia coli*
557 Strains. *J Bacteriol* **191**:5169–5179. doi:10.1128/JB.00458-09

558 Bodelón G, Palomino C, Fernández LÁ. 2013. Immunoglobulin domains in *Escherichia coli* and
559 other enterobacteria: From pathogenesis to applications in antibody technologies. *FEMS*
560 *Microbiol Rev*. doi:10.1111/j.1574-6976.2012.00347.x

561 Buchy P, Ascioglu S, Buisson Y, Datta S, Nissen M, Tambyah PA, Vong S. 2020. Impact of vaccines
562 on antimicrobial resistance. *International Journal of Infectious Diseases*.
563 doi:10.1016/j.ijid.2019.10.005

564 Buckner MMC, Ciusa ML, Piddock LJV. 2018. Strategies to combat antimicrobial resistance: Anti-
565 plasmid and plasmid curing. *FEMS Microbiol Rev*. doi:10.1093/femsre/fuy031

566 Butler T, Shuster CW, Dixon P. 1981. Treatment of experimental *Salmonella* typhimurium
567 infection with mecillinam and ampicillin. *Antimicrob Agents Chemother* **19**:328–331.
568 doi:10.1128/AAC.19.2.328

569 Call DR, Singer RS, Meng D, Broschat SL, Orfe LH, Anderson JM, Herndon DR, Kappmeyer LS,
570 Daniels JB, Besser TE. 2010. blaCMY-2-positive IncA/C plasmids from *Escherichia coli* and
571 *Salmonella* enterica are a distinct component of a larger lineage of plasmids. *Antimicrob*
572 *Agents Chemother* **54**:590–596. doi:10.1128/AAC.00055-09

573 Carattoli A. 2013. Plasmids and the spread of resistance. *International Journal of Medical*
574 *Microbiology*. doi:10.1016/j.ijmm.2013.02.001

575 Carattoli A. 2009. Resistance plasmid families in Enterobacteriaceae. *Antimicrob Agents*
576 *Chemother*. doi:10.1128/AAC.01707-08

577 Casasnovas JM, Margolles Y, Noriega MA, Guzmán M, Arranz R, Melero R, Casanova M, Corbera
578 JA, Jiménez-de-Oya N, Gastaminza P, Garaigorta U, Saiz JC, Martín-Acebes MÁ, Fernández
579 LÁ. 2022. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor
580 Binding Epitopes Preserved in Virus Variants Other Than Omicron. *Front Immunol* **13**.
581 doi:10.3389/fimmu.2022.863831

582 Ciofu O, Bagge N, Høiby N. 2002. Antibodies against β-lactamase can improve ceftazidime
583 treatment of lung infection with β-lactam-resistant *Pseudomonas aeruginosa* in a rat
584 model of chronic lung infection. *APMIS* **110**:881–891. doi:10.1034/j.1600-
585 0463.2002.1101207.x

586 Cook MA, Wright GD. 2022. The past, present, and future of antibiotics. *Sci Transl Med* **14**:7793.
587 doi:10.1126/scitranslmed.abo7793

588 Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli*
589 K-12 using PCR products. *Proc Natl Acad Sci U S A* **97**:6640–6645.
590 doi:10.1073/pnas.120163297

591 Dolejska M, Villa L, Poirel L, Nordmann P, Carattoli A. 2013. Complete sequencing of an IncHI1
592 plasmid encoding the carbapenemase NDM-1, the ArmA 16s RNA methylase and a
593 resistance-nodulation-cell division/multidrug efflux pump. *Journal of Antimicrobial*
594 *Chemotherapy* **68**:34–39. doi:10.1093/jac/dks357

595 Eda R, Nakamura M, Takayama Y, Maehana S, Nakano R, Yano H, Kitasato H. 2020. Trends and
596 molecular characteristics of carbapenemase-producing Enterobacteriaceae in Japanese
597 hospital from 2006 to 2015. *Journal of Infection and Chemotherapy* **26**:667–671.
598 doi:10.1016/j.jiac.2020.02.002

599 Fairman JW, Dautin N, Wojtowicz D, Liu W, Noinaj N, Barnard TJ, Udho E, Przytycka TM, Cherezov
600 V, Buchanan SK. 2012. Crystal Structures of the Outer Membrane Domain of Intimin and
601 Invasin from Enterohemorrhagic *E. coli* and Enteropathogenic *Y. pseudotuberculosis*.
602 *Structure* **20**:1233–1243. doi:10.1016/j.str.2012.04.011

603 Fernández-Alarcón C, Singer RS, Johnson TJ. 2011. Comparative genomics of multidrug
604 resistance-encoding incA/C plasmids from commensal and pathogenic *Escherichia coli*
605 from multiple animal sources. *PLoS One* **6**. doi:10.1371/journal.pone.0023415

606 Forde BM, Zowawi HM, Harris PNA, Roberts L, Ibrahim E, Shaikh N, Deshmukh A, Sid Ahmed MA,
607 Al Maslamani M, Cottrell K, Trembizki E, Sundac L, Yu HH, Li J, Schembri MA, Whiley DM,
608 Paterson DL, Beatson SA. 2018. Discovery of *mcr-1* -Mediated Colistin Resistance in a Highly
609 Virulent *Escherichia coli* Lineage. *mSphere* **3**. doi:10.1128/mSphere.00486-18

610 Fricke WF, Welch TJ, McDermott PF, Mammel MK, LeClerc JE, White DG, Cebula TA, Ravel J.
611 2009. Comparative genomics of the IncA/C multidrug resistance plasmid family. *J Bacteriol*
612 **191**:4750–4757. doi:10.1128/JB.00189-09

613 Frost I, Balachandran A, Paulin-Deschenaux S, Sati H, Hasso-Agopsowicz M. 2022. The approach
614 of World Health Organization to articulate the role and assure impact of vaccines against
615 antimicrobial resistance. *Hum Vaccin Immunother*. doi:10.1080/21645515.2022.2145069

616 Garcia-Just A, Miró L, Pérez-Bosque A, Amat C, Polo J, Pallàs M, Griñán-Ferré C, Moretó M. 2020.
617 Dietary spray-dried porcine plasma prevents cognitive decline in senescent mice and
618 reduces neuroinflammation and oxidative stress. *Journal of Nutrition* **150**:303–311.
619 doi:10.1093/jn/nxz239

620 Glass DS, Riedel-Kruse IH. 2018. A Synthetic Bacterial Cell-Cell Adhesion Toolbox for
621 Programming Multicellular Morphologies and Patterns. *Cell* **174**:649-658.e16.
622 doi:10.1016/j.cell.2018.06.041

623 Graf FE, Palm M, Warringer J, Farewell A. 2019. Inhibiting conjugation as a tool in the fight
624 against antibiotic resistance. *Drug Dev Res* **80**:19–23. doi:10.1002/ddr.21457

625 Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB,
626 Bendahman N, Hammers R. 1993. Naturally occurring antibodies devoid of light chains.
627 *Nature* **363**:446–448. doi:10.1038/363446a0

628 Holt KE, Phan MD, Baker S, Duy PT, Nga TVT, Nair S, Turner AK, Walsh C, Fanning S, Farrell-Ward
629 S, Dutta S, Kariuki S, WeillFranç FX, Parkhill J, Dougan G, Wain J. 2011. Emergence of a
630 globally dominant inchi1 plasmid type associated with multiple drug resistant typhoid.
631 *PLoS Negl Trop Dis* **5**. doi:10.1371/journal.pntd.0001245

632 Hüttener M, Hergueta J, Bernabeu M, Prieto A, Aznar S, Merino S, Tomás J, Juárez A. 2022. Roles
633 of Proteins Containing Immunoglobulin-Like Domains in the Conjugation of Bacterial
634 Plasmids. *mSphere* **7**. doi:10.1128/msphere.00978-21

635 Hüttener M, Prieto A, Aznar S, Bernabeu M, Glaría E, Valledor AF, Paytubi S, Merino S, Tomás J,
636 Juárez A. 2019. Expression of a novel class of bacterial Ig-like proteins is required for IncHI
637 plasmid conjugation. *PLoS Genet* **15**. doi:10.1371/journal.pgen.1008399

638 Ingle DJ, Ambrose RL, Baines SL, Duchene S, Gonçalves da Silva A, Lee DYJ, Jones M, Valcanis M,
639 Taiaroa G, Ballard SA, Kirk MD, Howden BP, Pearson JS, Williamson DA. 2021. Evolutionary
640 dynamics of multidrug resistant *Salmonella enterica* serovar 4,[5],12:i:- in Australia. *Nat*
641 *Commun* **12**. doi:10.1038/s41467-021-25073-w

642 Jovčevska I, Muyldermans S. 2020. The Therapeutic Potential of Nanobodies. *BioDrugs* **34**:11–
643 26. doi:10.1007/s40259-019-00392-z

644 Khanum S, Carbone V, Gupta SK, Yeung J, Shu D, Wilson T, Parlane NA, Altermann E, Estein SM,
645 Janssen PH, Wedlock DN, Heiser A. 2022. Mapping immunogenic epitopes of an adhesin-
646 like protein from Methanobrevibacter ruminantium M1 and comparison of empirical data
647 with in silico prediction methods. *Sci Rep* **12**:10394. doi:10.1038/s41598-022-14545-8

648 Koizumi N, Watanabe H. 2004. Leptospiral immunoglobulin-like proteins elicit protective
649 immunity. *Vaccine* **22**:1545–1552. doi:10.1016/j.vaccine.2003.10.007

650 Lawley TD, Gilmour MW, Gunton JE, Standeven LJ, Taylor DE. 2002. Functional and mutational
651 analysis of conjugative transfer region 1 (Tra1) from the IncHI1 plasmid R27. *J Bacteriol*
652 **184**:2173–2180. doi:10.1128/JB.184.8.2173-2180.2002

653 Lawley TD, Gilmour MW, Gunton JE, Tracz DM, Taylor DE. 2003. Functional and mutational
654 analysis of conjugative transfer region 2 (Tra2) from the IncHI1 plasmid R27. *J Bacteriol*
655 **185**:581–591. doi:10.1128/JB.185.2.581-591.2003

656 Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT. 2010.
657 Resurgence of colistin: A review of resistance, toxicity, pharmacodynamics, and dosing.
658 *Pharmacotherapy*. doi:10.1592/phco.30.12.1279

659 Lipsitch M, Siber GR. 2016. How can vaccines contribute to solving the antimicrobial resistance
660 problem? *mBio*. doi:10.1128/mBio.00428-16

661 Matamoros S, Van Hattem JM, Arcilla MS, Willemse N, Melles DC, Penders J, Vinh TN, Thi Hoa
662 N, Bootsma MCJ, Van Genderen PJ, Goorhuis A, Grobusch M, Molhoek N, Oude Lashof
663 AML, Stobberingh EE, Verbrugh HA, De Jong MD, Schultsz C. 2017. Global phylogenetic
664 analysis of *Escherichia coli* and plasmids carrying the mcr-1 gene indicates bacterial
665 diversity but plasmid restriction. *Sci Rep* **7**. doi:10.1038/s41598-017-15539-7

666 Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. 2010. Dramatic increase of third-
667 generation cephalosporin-resistant *E. coli* in German intensive care units: Secular trends in
668 antibiotic drug use and bacterial resistance, 2001 to 2008. *Crit Care* **14**. doi:10.1186/cc9062

669 Micoli F, Bagnoli F, Rappuoli R, Serruto D. 2021. The role of vaccines in combatting antimicrobial
670 resistance. *Nat Rev Microbiol* **19**:287–302. doi:10.1038/s41579-020-00506-3

671 Miró L, Rosell-Cardona C, Amat C, Polo J, Moretó M, Pérez-Bosque A. 2023. Dietary
672 supplementation with spray-dried animal plasma improves vaccine protection in aged
673 mice. *Front Nutr* **10**. doi:10.3389/fnut.2023.1050961

674 Morens DM, Folkers GK, Fauci AS. 2004. The challenge of emerging and re-emerging infectious
675 diseases. *Nature* **430**:242–249. doi:10.1038/nature02759

676 Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VAM, Torricelli
677 G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S,
678 Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, Serino L. 2010.
679 Identification of protective and broadly conserved vaccine antigens from the genome of
680 extraintestinal pathogenic *Escherichia coli*. *Proceedings of the National Academy of*
681 *Sciences* **107**:9072–9077. doi:10.1073/pnas.0915077107

682 Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao
683 P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G,
684 Kashef Hamadani BH, Kumaran EAP, McManigal B, Agarwal R, Akech S, Albertson S, Amuasi
685 J, Andrews J, Aravkin A, Ashley E, Bailey F, Baker S, Basnyat B, Bekker A, Bender R, Bethou
686 A, Bielicki J, Boonkasidecha S, Bukosia J, Carvalheiro C, Castañeda-Orjuela C, Chansamouth
687 V, Chaurasia S, Chiurchiù S, Chowdhury F, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E,
688 Cunningham M, Darboe S, Day NPJ, De Luca M, Dokova K, Dramowski A, Dunachie SJ,
689 Eckmanns T, Eibach D, Emami A, Feasey N, Fisher-Pearson N, Forrest K, Garrett D,
690 Gastmeier P, Giref AZ, Greer RC, Gupta V, Haller S, Haselbeck A, Hay SI, Holm M, Hopkins
691 S, Iregbu KC, Jacobs J, Jarovsky D, Javanmardi F, Khorana M, Kissoon N, Kobeissi E,
692 Kostyanev T, Krapp F, Krumkamp R, Kumar A, Kyu HH, Lim C, Limmathurotsakul D, Loftus
693 MJ, Lunn M, Ma J, Mturi N, Munera-Huertas T, Musicha P, Mussi-Pinhata MM, Nakamura
694 T, Nanavati R, Nangia S, Newton P, Ngoun C, Novotney A, Nwakanma D, Obiero CW, Olivas-
695 Martinez A, Olliaro P, Ooko E, Ortiz-Brizuela E, Peleg AY, Perrone C, Plakkal N, Ponce-de-
696 Leon A, Raad M, Ramdin T, Riddell A, Roberts T, Robotham JV, Roca A, Rudd KE, Russell N,
697 Schnall J, Scott JAG, Shivamallappa M, Sifuentes-Osornio J, Steenkeste N, Stewardson AJ,
698 Stoeva T, Tasak N, Thaiprakong A, Thwaites G, Turner C, Turner P, van Doorn HR, Velaphi
699 S, Vongpradith A, Vu H, Walsh T, Waner S, Wangrangsimakul T, Wozniak T, Zheng P,
700 Sartorius B, Lopez AD, Stergachis A, Moore C, Dolecek C, Naghavi M. 2022. Global burden
701 of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* **399**:629–
702 655. doi:10.1016/S0140-6736(21)02724-0

703 Muyldermans S. 2021. Applications of Nanobodies. *Annu Rev Anim Biosci* **9**:401–421.
704 doi:10.1146/annurev-animal-021419-083831

705 Muyldermans S. 2013. Nanobodies: Natural single-domain antibodies. *Annu Rev Biochem*.
706 doi:10.1146/annurev-biochem-063011-092449

707 Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, Smith S, Bertoldi I, Pastorello I,
708 Ferlenghi I, Fontana MR, Frankel G, Mobley HLT, Rappuoli R, Pizza M, Serino L, Soriani M.
709 2012. FdeC, a novel broadly conserved *Escherichia coli* adhesin eliciting protection against
710 urinary tract infections. *mBio* **3**. doi:10.1128/mBio.00010-12

711 Novick RP, Richmond MH. 1965. Nature and Interactions of the Genetic Elements Governing
712 Penicillinase Synthesis in *Staphylococcus aureus*. *J Bacteriol* **90**:467–480.
713 doi:10.1128/jb.90.2.467-480.1965

714 Parvez S, Khan AU. 2018. Hospital sewage water: a reservoir for variants of New Delhi metallo-
715 β-lactamase (NDM)- and extended-spectrum β-lactamase (ESBL)-producing
716 Enterobacteriaceae. *Int J Antimicrob Agents* **51**:82–88.
717 doi:10.1016/j.ijantimicag.2017.08.032

718 Phan M-D, Wain J. 2008. IncHI plasmids, a dynamic link between resistance and pathogenicity.
719 *The Journal of Infection in Developing Countries* **2**. doi:10.3855/jidc.221

720 Piñero-Lambea C, Bodelón G, Fernández-Periáñez R, Cuesta AM, Álvarez-Vallina L, Fernández LÁ.
721 2015. Programming Controlled Adhesion of *E. coli* to Target Surfaces, Cells, and Tumors
722 with Synthetic Adhesins. *ACS Synth Biol* **4**:463–473. doi:10.1021/sb500252a

723 Qamar MU, Ejaz H, Walsh TR, Shah AA, Al Farraj DA, Alkufeidy RM, Alkubaisi NA, Saleem S, Jahan
724 S. 2021. Clonal relatedness and plasmid profiling of extensively drug-resistant New Delhi
725 metallo-β-lactamase-producing *Klebsiella pneumoniae* clinical isolates. *Future Microbiol*
726 **16**:229–239. doi:10.2217/fmb-2020-0315

727 Ren W, Yin J, Duan J, Liu G, Zhu X, Chen S, Li T, Wang S, Tang Y, Hardwidge PR. 2014. Mouse
728 intestinal innate immune responses altered by enterotoxigenic *Escherichia coli* (ETEC)
729 infection. *Microbes Infect* **16**:954–961. doi:10.1016/j.micinf.2014.09.005

730 Robledo M, Álvarez B, Cuevas A, González S, Ruano-Gallego D, Fernández LÁ, de la Cruz F. 2022.
731 Targeted bacterial conjugation mediated by synthetic cell-to-cell adhesions. *Nucleic Acids*
732 *Res* **50**:12938–12950. doi:10.1093/nar/gkac1164

733 Rosell-Cardona C, Amat C, Griñán-Ferré C, Polo J, Pallàs M, Pérez-Bosque A, Moretó M, Miró L.
734 2022. The Neuroprotective Effects of Spray-Dried Porcine Plasma Supplementation Involve
735 the Microbiota−Gut−Brain Axis. *Nutrients* **14**. doi:10.3390/nu14112211

736 Rossi O, Dybowski R, Maskell DJ, Grant AJ, Restif O, Mastroeni P. 2017. Within-host
737 spatiotemporal dynamics of systemic *Salmonella* infection during and after antimicrobial
738 treatment. *Journal of Antimicrobial Chemotherapy* **72**:3390–3397. doi:10.1093/jac/dkx294

739 Rossolini GM, Mantengoli E, Docquier J-D, Musmanno RA, Coratza G. 2007. Epidemiology of
740 infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. *New*
741 *Microbiol* **30**:332–9.

742 Rozwandowicz M, Brouwer MSM, Fischer J, Wagenaar JA, Gonzalez-Zorn B, Guerra B, Mevius DJ,
743 Hordijk J. 2018. Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae.
744 *Journal of Antimicrobial Chemotherapy* **73**:1121–1137. doi:10.1093/jac/dkx488

745 Salema V, Fernández LÁ. 2017. *Escherichia* coli surface display for the selection of nanobodies.
746 *Microb Biotechnol* **10**:1468–1484. doi:10.1111/1751-7915.12819

747 Salema V, López-Guajardo A, Gutierrez C, Mencía M, Fernández LÁ. 2016. Characterization of
748 nanobodies binding human fibrinogen selected by *E. coli* display. *J Biotechnol* **234**:58–65.
749 doi:10.1016/j.jbiotec.2016.07.025

750 Salema V, Marín E, Martínez-Arteaga R, Ruano-Gallego D, Fraile S, Margolles Y, Teira X, Gutierrez
751 C, Bodelón G, Fernández LÁ. 2013. Selection of Single Domain Antibodies from Immune
752 Libraries Displayed on the Surface of *E. coli* Cells with Two β-Domains of Opposite
753 Topologies. *PLoS One* **8**:e75126. doi:10.1371/journal.pone.0075126

754 Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative CT method. *Nat*
755 *Protoc* **3**:1101–1108. doi:10.1038/nprot.2008.73

756 Senna JPM, Roth DM, Oliveira JS, Machado DC, Santos DS. 2003. Protective immune response
757 against methicillin resistant *Staphylococcus aureus* in a murine model using a DNA vaccine
758 approach. *Vaccine* **21**:2661–2666. doi:10.1016/S0264-410X(02)00738-7

759 Sherburne CK, Lawley TD, Gilmour MW, Blattner FR, Burland V, Grotbeck E, Rose DJ, Taylor DE.
760 2000. The complete DNA sequence and analysis of R27, a large IncHI plasmid from
761 *Salmonella* typhi that is temperature sensitive for transfer. *Nucleic Acids Res* **28**:2177–86.
762 doi:10.1093/nar/28.10.2177

763 Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J.
764 2008. The epidemic of antibiotic-resistant infections: A call to action for the medical
765 community from the infectious diseases society of America. *Clinical Infectious Diseases*.
766 doi:10.1086/524891

767 Suzuki H, Yano H, Brown CJ, Top EM. 2010. Predicting plasmid promiscuity based on genomic
768 signature. *J Bacteriol* **192**:6045–6055. doi:10.1128/JB.00277-10

769 Tanmoy AM, Westeel E, De Bruyne K, Goris J, Rajoharison A, Sajib MSI, Van Belkum A, Saha SK,
770 Komurian-Pradel F, Endtz HP. 2018. *Salmonella enterica* Serovar Typhi in Bangladesh:
771 Exploration of Genomic Diversity and Antimicrobial Resistance. doi:10.1128/mBio.00105

772 Thomas CM, Nielsen KM. 2005. Mechanisms of, and barriers to, horizontal gene transfer
773 between bacteria. *Nat Rev Microbiol*. doi:10.1038/nrmicro1234

774 Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. 2008. Efficient
775 generation of monoclonal antibodies from single human B cells by single cell RT-PCR and
776 expression vector cloning. *J Immunol Methods* **329**:112–124.
777 doi:10.1016/j.jim.2007.09.017

778 Troisi M, Andreano E, Sala C, Kabanova A, Rappuoli R. 2020. Vaccines as remedy for antimicrobial
779 resistance and emerging infections. *Curr Opin Immunol*. doi:10.1016/j.coi.2020.09.003

780 Villa L, Poirel L, Nordmann P, Carta C, Carattoli A. 2012. Complete sequencing of an IncH plasmid
781 carrying the bla ndm-1, bla ctx-m-15 and qnrB1 genes. *Journal of Antimicrobial*
782 *Chemotherapy* **67**:1645–1650. doi:10.1093/jac/dks114

783 Vrancianu CO, Popa LI, Bleotu C, Chifiriuc MC. 2020. Targeting Plasmids to Limit Acquisition and
784 Transmission of Antimicrobial Resistance. *Front Microbiol*. doi:10.3389/fmicb.2020.00761

785 Wang J, Stephan R, Zurfluh K, Hächler H, Fanning S. 2015. Characterization of the genetic
786 environment of blaESBL genes, integrons and toxin-antitoxin systems identified on large
787 transferrable plasmids in multi-drug resistant *Escherichia coli*. *Front Microbiol* **6**.
788 doi:10.3389/fmicb.2014.00716

789 Wang Y, Tian GB, Zhang R, Shen Y, Tyrrell JM, Huang X, Zhou H, Lei L, Li HY, Doi Y, Fang Y, Ren H,
790 Zhong LL, Shen Z, Zeng KJ, Wang S, Liu JH, Wu C, Walsh TR, Shen J. 2017. Prevalence, risk
791 factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in
792 patients and healthy adults from China: an epidemiological and clinical study. *Lancet Infect*
793 *Dis* **17**:390–399. doi:10.1016/S1473-3099(16)30527-8

794 Welch TJ, Fricke WF, McDermott PF, White DG, Rosso ML, Rasko DA, Mammel MK, Eppinger M,
795 Rosovitz MJ, Wagner D, Rahalison L, LeClerc JE, Hinshaw JM, Lindler LE, Cebula TA, Carniel
796 E, Ravel J. 2007. Multiple antimicrobial resistance in plague: An emerging public health risk.
797 *PLoS One* **2**. doi:10.1371/journal.pone.0000309

798 World Health Organization. 2019. Typhoid vaccines: WHO position paper, March 2018 –
799 Recommendations. *Vaccine* **37**:214–216. doi:10.1016/j.vaccine.2018.04.022

800 Yuki Y, Zuo F, Kurokawa S, Uchida Y, Sato S, Sakon N, Hammarström L, Kiyono H, Marcotte H.
801 2023. Lactobacilli as a Vector for Delivery of Nanobodies against Norovirus Infection.
802 *Pharmaceutics* **15**. doi:10.3390/pharmaceutics15010063

803 Zarantonelli ML, Antignac A, Lancellotti M, Guiyoule A, Alonso JM, Taha MK. 2006.
804 Immunogenicity of meningococcal PBP2 during natural infection and protective activity of
805 anti-PBP2 antibodies against meningococcal bacteraemia in mice. *Journal of Antimicrobial*
806 *Chemotherapy* **57**:924–930. doi:10.1093/jac/dkl066

807 Zhang Zhiren, Guo H, Li Xiaodong, Li W, Yang G, Ni W, Zhan M, Lu L, Zhang Zhenlin, Li Xiaobin,
808 Zhou Z. 2021. Genetic Diversity and Characteristics of blaNDM-Positive Plasmids in
809 *Escherichia coli*. *Front Microbiol* **12**. doi:10.3389/fmicb.2021.729952

810 Zheng B, Dong H, Xu H, Lv J, Zhang J, Jiang X, Du Y, Xiao Y, Li L. 2016. Coexistence of MCR-1 and
811 NDM-1 in Clinical *Escherichia coli* Isolates. *Clinical Infectious Diseases*.
812 doi:10.1093/cid/ciw553

813

814 **Acknowledgments**

815 This work was supported by grants from Fundació "La Marató TV3," Spain (project 201818 10),
816 CERCA Program/Generalitat de Catalunya to AJ, PID2021-124676NB-I00 from the Ministerio de
817 Economía, Industria y Competitividad to SM and JT. Work in the laboratory of LAF is supported
818 by grants PLEC2021-007739 from MCIN/AEI NextGeneration EU/ PRTR and FET Open 965018-
819 BIOCELLPHE from the European Union's Horizon 2020 Future and Emerging Technologies
820 research and innovation program. LM and APB are members of the Institut de Recerca en
821 Nutrició, i Seguretat Alimentària (INSA-UB), which is recognized as a Maria de Maeztu Unit of
822 Excellence and funded by MICIN/AEI/FEDER (CEX2021-001234-M).

823

824 **Contributions**

825 Genetic manipulations, conjugative transfer of the RSP plasmid and purification of the variants
826 of the RSP protein were conducted by A. Prieto, M. Hüttener, D. Salguero and M. Bernabeu. *In*
827 *vivo* experiments with mice were conducted by L. Miró and A. Pérez-Bosque. Electron
828 microscopy studies were conducted by S. Merino and J. Tomás. Selection of clones producing
829 anti-RSP nanobodies and the analysis of the effect of the obtained nanobodies on the
830 conjugative transfer of the RSP plasmid were performed by Y. Margolles, L.A. Fernández and A.
831 Prieto. The initial manuscript draft was written by A. Prieto, A. Pérez-Bosque and A. Juárez. A.
832 Prieto, A. Pérez-Bosque, L.A. Fernández, M. Hüttener, and A. Juárez edited the final version. A.
833 Juárez was the PI of the project.

834 **Ethics**

835 The dromedary camel immunization protocol followed European Union and Spanish guidelines
836 of animal experimentation and was approved by the Ethics Committee for Animal
837 Experimentation from University of Las Palmas de Gran Canaria and the Consejería de
838 Agricultura, Pesca y Aguas of the Canary Islands Goverment (reference OEBA_ULPGC_20-2023).
839 Experimentation with mice was conducted at Animal Facility of Faculty of Pharmacy and Food
840 Science. Experiments were approved by the Ethics Committee of Animal Experimentation of the
841 University of Barcelona (Ref. 170/20). Animals were handled in strict accordance with the
842 guidelines of the European Community 86/609/CEE.

843 **Competing interests**

844 The authors declare no competing interests.

845

846 **Figures**



847

848 **Figure 1. Infection of mice with the *S.* Typhimurium SL1344 and *S.* Typhimurium (pHCM1)**
849 **strains.** Survival rate **(A)**, body weight evolution **(B)**, disease index **(C)** and proinflammatory
850 cytokine expression in spleen, *Il-6* **(D)**, *Il-1β* **(E)** and *Tnf-α* **(F)**. Groups treated with ampicillin
851 (Amp) are indicated with **+Amp**. In panel (A), survival rate of control animals and those infected
852 with the *S.* Typhimurium SL1344 (WT) strain and treated with Amp, are 100%. Animals infected
853 with the *S.* Typhimurium (pHCM1) strain have the same survival rate independently of the
854 treatment with Amp. Results are expressed as mean ± SEM (n= 6-8 animals). Means without a
855 common letter differ, P<0.05.

856


A
Evolution body weight
Grams (g)
Weeks of age
Non-Imm
Imm
B
Total IgG in serum
mg/mL
Non-Imm
Imm
C
RSP specific IgG in serum
O.D. 492 nm
a
nd
b
D
Total IgA in jejunum content
mg/mL
a
b
E
RSP specific IgA in jejunum content
O.D. 492 nm
a
b
F
Total IgA in colon content
mg/mL
G
RSP specific IgA in colon content
O.D. 492 nm
a
b
H
Total IgA in feces
mg/mL
a
b
I
RSP specific IgA in feces
O.D. 492 nm
a
b

857

858

859 **Figure 2. Effect of immunization with the RSP protein on body weight evolution (A) and**
860 **immunoglobulin concentration (B-I).** Open bars represent non-immunized (**No-Imm**) mice;
861 solid bars represent immunized (**Imm**) mice. Results are expressed as mean ± SEM (n= 6-8
862 animals). IgA, immunoglobulin A; IgG, immunoglobulin G; nd, non-detected. Means without a
863 common letter differ, $P<0.05$.

864

865



866

867 **Figure 3. Survival rate (A), body weight change (B) and clinical signs (C) after challenge with**

868 **the SL1344 (pHCM1) strain.** Open bars/plots represent non-immunized (**No-Imm**) mice; solid

869 bars/plots represent immunized (**Imm**) mice. In panel B, results are expressed as mean ± SEM

870 (n= 12-14 animals). Means without a common letter differ, P<0.05.



871

872 **Figure 4. Immunoglobulin concentration and cytokine expression in the gastrointestinal tract**
873 **after RSP immunization and challenge with *Salmonella.*** Total IgA concentration in jejunum
874 content **(A)**, in colon content **(B)** and in feces **(C)**. RSP-specific IgA titers in jejunum content **(D)**,
875 in colon content **(E)** and in feces **(F)**. *Il-1β* **(G)**, *Il-6* **(H)** and *Tnf-α* **(I)** expression in colon
876 mucosa. Open bars represent non-immunized (**Non-Imm**) mice; solid bars represent immunized
877 (**Imm**) mice. Results are expressed as means ± SEMs (n= 10–12 animals). Means without a
878 common letter differ, P<0.05. IgA, immunoglobulin A; IgG, immunoglobulin G; Il, interleukin; Int,
879 interaction between both factors; Tnf-α, tumor necrosis factor alpha.



Figure 5. Immunoglobulin concentration, spleen weight, *Salmonella* counts in spleen tissue and cytokine expression in spleen tissue after immunization with the RSP protein and challenge with the SL1344 (pHCM1) strain. Total IgG concentration **(A)** and RSP-specific IgG titers **(B)** in plasma. Spleen weight **(C)** and *Salmonella* counts in spleen tissue **(D)**. *Il-1β* **(E)**, *Il-6* **(F)** and *Tnf-α* **(G)** expression in spleen tissue. Results are expressed as means ± SEMs (n= 12-14 animals). Means without a common letter differ, P<0.05. IgA, immunoglobulin A; IgG, immunoglobulin G; Il, interleukin; nd, non-detected; Tnf-α, tumor necrosis factor alpha.



Figure 6. Selection of RSP-binding Nbs from immune libraries displayed on the surface of *E. coli.* (A) Flow cytometry analysis of the enrichment of bacterial population displaying Nb libraries generated after the immunization of dromedaries with the C-terminal domain of the RSP protein. 3 rounds of selection with the RSP protein by magnetic cell sorting (MACS) and one round of fluorescence activated cell sorting (FACS) were performed, in which bacteria were incubated with 50 nM of biotin-labeled RSP (or 100 nM of fibrinogen used as a specificity control) and stained with Streptavidin-APC. **(B)** Flow cytometry of the individual bacterial clones selected from the immune library. The bacterial surface display of the corresponding nanobody was

897 detected using an anti-c-myc monoclonal antibody. The binding of biotin-labeled antigens to
898 Nbs displayed on bacteria was performed with the incubation of bacterial cells with 50 nM of
899 biotin-labeled RSP.



Figure 7. Analysis of the interaction of the VHH-RSP#3 isolated in the immune library with the native RSP protein at a macro and microscopic level. (A) Assay of the ability of *E. coli* DH10BT1R cells expressing nanobodies on its surface to agglutinate cells of the *S*. Typhimurium SL1344 (R27) strain. Blue arrow marks the aggregation of bacteria after the interaction of *E. coli* cells producing nanobodies directed against the RSP protein (VHH-RSP #3) and *Salmonella* cells harboring the R27 plasmid. **(B)** Transmission electron microscopy imaging mixtures of *E. coli* DH10BT1R cells expressing nanobodies against the RSP protein on its surface and cells of the *S*. Typhimurium SL1344 strain, harboring or not the R27 plasmid. The studies were performed by labeling the nanobodies producing bacteria (*E. coli* DH10BT1R) with a mouse antibody anti c-myc tag and goat anti-mouse IgG conjugated to 12 nm gold particles. Blue bars represent 1 µm while black bars represent 2 µm.

912



913

914 **Figure 8. Characterization of the purified VHH-RSP#3 as a specific binder to the RSP protein.**

915 **(A)** Purification of Nb3-Fc by affinity column**.** Coomassie staining of the SDS-PAGE (10%) showing

916 the purified Nb-RSP #3-Fc from transfected mammalian cell culture supernatants. Molecular

917 weight markers are indicated on the left. **(B)** ELISA showing the binding capacity of the purified

918 VHH-RSP#3-Fc to the RSP or BSA protein. The plot represents the OD values at 490 nm obtained

919 with the indicated concentrations of the purified Nb3-Fc after 1 hour of interaction with the

920 corresponding antigen.

921



922

923 **Figure 9. Interference of *E. coli* DH10BT1R cells expressing nanobodies on its surface with the**
924 **conjugative transfer of the R27 plasmid in *Salmonella.*** R27 plasmid was conjugated from a
925 donor strain (SL1344) to a recipient strain (SL1344 *ibpA::lacZ-Km*^{r}) with the absence or presence
926 of the interferent strains *E. coli* DH10BT1R, plasmid-free clone; *E. coli* DH10BT1R (pNVFib1),
927 clone expressing a fibrinogen-specific VHH; *E. coli* DH10BT1R (pNeae2 VHH-RSP #3), clone
928 expressing RSP-specific VHH. Means without a common letter differ, $P<0.05$.